Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0SZXVK)
| ADC Name |
PF-08046032
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
PF-08046032
Click to Show/Hide
|
|||||
| Organization |
Pfizer (Top20 MNC) (Originator)
|
|||||
| Drug Status |
Phase 1
|
|||||
| Drug-to-Antibody Ratio |
4
|
|||||
| Structure |
|
|||||
| Antibody Name |
A detuned-affinity anti-CD25 mAb
|
Antibody Info | ||||
| Antigen Name |
Interleukin-2 receptor subunit alpha (IL2RA)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Payload Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Mc-Val-Cit-PABC
|
Linker Info | ||||
| Conjugate Type |
Random Cysteines
|
|||||
| Combination Type |
vedotin
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
| Indication | Phase 1 | Phase 2 | Phase 3 | Approved | |||
|---|---|---|---|---|---|---|---|
| Unspecific solid tumor |
1 Trials
|
||||||
| Diffuse large B-cell lymphoma |
2 Trials
|
||||||
| Mature T-cell lymphoma |
2 Trials
|
||||||
| Hodgkin lymphoma |
2 Trials
|
||||||
| Lung cancer |
2 Trials
|
||||||
| Melanoma |
1 Trials
|
||||||
| Head and neck cancer |
2 Trials
|